Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M196Revenue $M12.5Net Margin (%)-162.8Z-Score-5.6
Enterprise Value $M129EPS $-0.5Operating Margin %-220.8F-Score3
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-163.7Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio3.0Cash flow > EarningsN
Price/Sales13.65-y EBITDA Growth Rate %-22.5Current Ratio3.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-25.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M62.8ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with THLD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THLDJean-Marie Eveillard 2014-09-30 Add$3.75 - $5.03
($4.2)
$ 3.12-26%Add 36.46%1,091,700
THLDJean-Marie Eveillard 2014-03-31 Add0.01%$4.34 - $5.72
($4.92)
$ 3.12-37%Add 250%700,000
THLDJean-Marie Eveillard 2012-12-31 Buy $3.98 - $6.55
($4.67)
$ 3.12-33%New holding, 200000 sh.200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THLD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
THLD Jean-Marie Eveillard 2014-09-301,091,7001.740.01+36.46%
Premium Most recent portfolio changes are included for Premium Members only!


THLD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Davar NipunVice President 2014-10-13Buy3,000$2.99-1view
GAITHER JAMES C10% Owner 2014-10-01Sell231,287$3.77-21.49view
YOUNGER WILLIAM H JR10% Owner 2014-10-01Sell242,396$3.77-21.49view
WHITE JAMES N10% Owner 2014-10-01Sell239,538$3.77-21.49view
SWEET DAVID E10% Owner 2014-10-01Sell229,154$3.77-21.49view
Speiser Michael L10% Owner 2014-10-01Sell227,228$3.77-21.49view
SHEEHAN ANDREW T10% Owner 2014-10-01Sell230,352$3.77-21.49view
Pullara Samuel J III10% Owner 2014-10-01Sell226,657$3.77-21.49view
SUTTER HILL VENTURES10% Owner 2014-10-01Sell226,657$3.77-21.49view
Dyckerhoff Stefan A10% Owner 2014-10-01Sell226,657$3.77-21.49view

Press Releases about THLD :

    Quarterly/Annual Reports about THLD:

    News about THLD:

    Articles On GuruFocus.com
    Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus De Dec 06 2014 
    Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in Dece Nov 25 2014 
    Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevaciz Nov 17 2014 
    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of Previo Nov 11 2014 
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare Conferenc Nov 10 2014 
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented Nov 06 2014 
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at Nov 03 2014 
    Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in th Nov 03 2014 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

    More From Other Websites
    Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus... Dec 06 2014
    Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus... Dec 06 2014
    Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in... Nov 25 2014
    Threshold Pharmaceuticals Announces Presentations and Webcasts at Upcoming Investor Meetings in... Nov 25 2014
    THLD: Threshold’s Provides an Update on its Phase I/II Trial using TH-302 in Glioblastoma Nov 17 2014
    Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus... Nov 17 2014
    Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus... Nov 17 2014
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 12 2014
    THRESHOLD PHARMACEUTICALS INC Financials Nov 11 2014
    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of... Nov 11 2014
    Threshold Pharmaceuticals Receives FDA Fast Track Designation for TH-302 for the Treatment of... Nov 11 2014
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare... Nov 10 2014
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Stifel 2014 Healthcare... Nov 10 2014
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented... Nov 06 2014
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Multiple Myeloma to Be Presented... Nov 06 2014
    Threshold: A Biopharmaceutical Company focused on Hypoxia-targeted Cancer Therapy Nov 06 2014
    10-Q for Threshold Pharmaceuticals, Inc. Nov 05 2014
    Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at... Nov 03 2014
    Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in... Nov 03 2014
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK